Literature DB >> 17996323

Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: insights from echocardiography and exercise cardiac performance evaluation.

Vittorio Palmieri1, Brunella Capaldo, Cesare Russo, Michele Iaccarino, Salvatore Pezzullo, Gabriele Quintavalle, Giovanni Di Minno, Gabriele Riccardi, Aldo Celentano.   

Abstract

OBJECTIVES: Left ventricular (LV) diastolic dysfunction is considered the earliest manifestation of diabetic cardiomyopathy. Whether LV abnormalities identified at rest by echocardiography predict peak exercise LV performance in uncomplicated type 1 diabetes mellitus (DM1) is largely unknown. RESEARCH DESIGN AND METHODS: We evaluated LV size, mass, and functions and peak exercise LV performance in 25 subjects with uncomplicated DM1 (median disease duration 13.5 years, 1-30 years) and in 56 non-DM subjects (24 hypertensive (HT) and 32 normotensive (NT)). Overt coronary heart disease, significant microangiopathy and central autonomic neuropathy were minimized by exclusion criteria. Peak exercise LV stroke index (SVi), cardiac index (COi), LV ejection fraction (EF), LV end-diastolic and end-systolic volumes were assessed noninvasively. No subject was on cardiovascular medications at the time of evaluation.
RESULTS: In our study, DM1 did not show LV hypertrophy or impaired LV systolic function at rest. Prevalence of diastolic dysfunction was 8% among DM1, 18% among NT and 50% among HT. Pre-exercise heart rate, SVi, COi, and peak exercise blood pressure (BP) and heart rate were comparable among the three groups, but peak exercise LV EF, SVi and COi were lower in DM1 than in HT and NT independent to covariates (p<0.05). In separate analyses, DM1 predicted lower peak exercise SVi (B=-6.2) and COi (B=-1.6, both p<0.05) independently. Within DM1, glycated haemoglobin (HbA1c) and disease duration did not predict peak exercise LV systolic function.
CONCLUSIONS: Our study suggests that uncomplicated DM1 may be associated with subnormal LV contractility reserve, which might not be predicted by LV dysfunction evaluated at rest.

Entities:  

Mesh:

Year:  2007        PMID: 17996323     DOI: 10.1016/j.diabres.2007.09.014

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  17 in total

1.  Myocardial structure, function, and scar in patients with type 1 diabetes mellitus.

Authors:  Evrim B Turkbey; Jye-Yu C Backlund; Saul Genuth; Aditya Jain; Cuilian Miao; Patricia A Cleary; John M Lachin; David M Nathan; Rob J van der Geest; Elsayed Z Soliman; Chia-Ying Liu; João A C Lima; David A Bluemke
Journal:  Circulation       Date:  2011-09-26       Impact factor: 29.690

2.  Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice.

Authors:  Marco Meloni; Betty Descamps; Andrea Caporali; Lorena Zentilin; Ilaria Floris; Mauro Giacca; Costanza Emanueli
Journal:  Diabetes       Date:  2012-01       Impact factor: 9.461

Review 3.  Diabetic cardiomyopathy, causes and effects.

Authors:  Sihem Boudina; Evan Dale Abel
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

4.  Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach.

Authors:  Falah Aboukhoudir; Sofiene Rekik
Journal:  Int J Cardiovasc Imaging       Date:  2011-08-18       Impact factor: 2.357

5.  Diabetic cardiomyopathy--fact or fiction?

Authors:  B Maisch; P Alter; S Pankuweit
Journal:  Herz       Date:  2011-03       Impact factor: 1.443

6.  Enhanced skeletal muscle expression of extracellular superoxide dismutase mitigates streptozotocin-induced diabetic cardiomyopathy by reducing oxidative stress and aberrant cell signaling.

Authors:  Jarrod A Call; Kristopher H Chain; Kyle S Martin; Vitor A Lira; Mitsuharu Okutsu; Mei Zhang; Zhen Yan
Journal:  Circ Heart Fail       Date:  2014-12-11       Impact factor: 8.790

7.  Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy.

Authors:  Karina Huynh; Julie R McMullen; Tracey L Julius; Joon Win Tan; Jane E Love; Nelly Cemerlang; Helen Kiriazis; Xiao-Jun Du; Rebecca H Ritchie
Journal:  Diabetes       Date:  2010-03-09       Impact factor: 9.461

8.  Low total haemoglobin mass, blood volume and aerobic capacity in men with type 1 diabetes.

Authors:  Anne S Koponen; Juha E Peltonen; Marja K Päivinen; Jyrki M Aho; Harriet J Hägglund; Arja L Uusitalo; Harri J Lindholm; Heikki O Tikkanen
Journal:  Eur J Appl Physiol       Date:  2012-11-06       Impact factor: 3.078

Review 9.  Cardiovascular disease in young People with Type 1 Diabetes: Search for Cardiovascular Biomarkers.

Authors:  Michal Schäfer; Kristen J Nadeau; Jane E B Reusch
Journal:  J Diabetes Complications       Date:  2020-06-06       Impact factor: 2.852

10.  Aortic stiffness is associated with cardiac function and cerebral small vessel disease in patients with type 1 diabetes mellitus: assessment by magnetic resonance imaging.

Authors:  Saskia G C van Elderen; A Brandts; J J M Westenberg; J van der Grond; J T Tamsma; M A van Buchem; J A Romijn; L J M Kroft; J W A Smit; A de Roos
Journal:  Eur Radiol       Date:  2009-11-14       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.